一、审议通过《关于批准本次交易相关审计报告、资产评估报告和备考审 阅报告的议案》 为推进实施本次交易，致同会计师事务所（特殊普通合伙）出具了致同审字 （2025）第440A033616号《上海量義技术有限公司2023年、2024年度及2025年1-6 月审计报告》、北京中同华资产评估有限公司出具的中同华评报字（2025）第 071406号《广州禾信仪器股份有限公司拟发行股份及支付现金购买资产所涉及的 上海量羲技术有限公司股东全部权益价值资产评估报告》、致同会计师事务所（特 殊普通合伙）出具的致同审字（2025）第440A033743号《广州禾信仪器股份有限 公司2024年度、2025年1-6月备考合并财务报表审阅报告》，该等报告将作为相应 申报文件进行报送及信息披露。 广州禾信仪器股份有限公司 第四届董事会独立董事专门会议第一次会议决议 广州禾信仪器股份有限公司(以下简称"公司")第四届董事会独立董事专门 会议第一次会议通知于 2025 年 7 月 18 日以邮件方式发出，并于 2025 年 7 月 25 日以通讯表决形式召开。本次会议由全体独立董事共同推举的陈明先生召集和主 持，会议应出席独立董事 3 人， ...

证券代码：688622 证券简称：禾信仪器 公告编号：2025-042 广州禾信仪器股份有限公司 第四届董事会第二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 广州禾信仪器股份有限公司（以下简称"公司"）第四届董事会第二次会议 于 2025 年 7 月 25 日以邮件方式发出通知，并于 2025 年 8 月 4 日以现场结合通 讯表决形式召开。会议由董事长周振先生主持，会议应到董事 9 名，实到董事 9 名。出席会议人数符合《中华人民共和国公司法》（以下简称"《公司法》"） 和《广州禾信仪器股份有限公司章程》（以下简称"《公司章程》"）等规定， 本次会议的召开及会议形成的决议合法、有效。 二、董事会会议审议情况 出席董事经表决，一致通过如下决议： (一)审议通过《关于 2025 年半年度报告及其摘要的议案》 公司《2025 年半年度报告》及其摘要的编制和审议符合相关法律法规及《公 司章程》的有关规定，报告真实、准确、完整地反映了公司的财务状况和经营情 况，不存在虚假记载、误导性陈述 ...

报告期内主要受市场大环境调整影响，下游投资节奏及需求放缓等因素对公司经营业绩产生一定影响， 公司营业收入同比下降。 智通财经APP讯，禾信仪器(688622.SH)披露2025年半年度报告，报告期实现营收5282万元，同比下降 48.88%;归母净利润亏损1746万元，同比收窄;扣非净利润亏损1984万元，同比收窄;基本每股收益-0.25 元。 ...

证券时报·数据宝统计显示，禾信仪器所属的机械设备行业，目前整体涨幅为0.02%，行业内，目前股价 上涨的有359只，涨幅居前的有东杰智能、福事特、德固特等，涨幅分别为20.00%、10.28%、9.98%。 股价下跌的有212只，跌幅居前的有中化装备、方盛股份、拓山重工等，跌幅分别为9.97%、8.91%、 8.13%。 禾信仪器股价创出历史新高，截至15:00，该股上涨3.60%，股价报103.60元，成交量147.41万股，成交 金额1.48亿元，换手率2.09%，该股最新A股总市值达72.97亿元，该股A股流通市值72.97亿元。 两融数据显示，该股最新（7月31日）两融余额为1.75亿元，其中，融资余额为1.75亿元，近10日减少 1586.20万元，环比下降8.33%。 公司发布的一季报数据显示，一季度公司共实现营业收入3167.30万元，同比下降32.04%，实现净利 润-706.88万元，同比增长52.93%，基本每股收益为-0.1000元。（数据宝） （文章来源：证券时报网） ...

Group 1 - The stock of HeXin Instruments (688622) closed at 96.02 yuan on July 29, reaching the daily limit with a trading volume of 2.58 billion yuan and a turnover rate of 4.05% [2] - The stock was listed on the daily trading list due to a price increase of 15% at the close [2] - The top five trading departments accounted for a total transaction amount of 1.28 billion yuan, with a net buying amount of 335.27 million yuan [2][3] Group 2 - The main capital inflow for the stock was 9.68 million yuan for the day [3] - The largest buying department was the Shanghai-Hong Kong Stock Connect, with a buying amount of 26.99 million yuan, while the largest selling department was also the Shanghai-Hong Kong Stock Connect, with a selling amount of 11.35 million yuan [3] - Specific buying and selling amounts from various departments were detailed, indicating significant institutional interest [3]

Market Overview - The Shanghai Composite Index closed at 3595.19 points, slightly down by 0.08%, and remains above the six-month moving average [1] - The total trading volume of A-shares reached 1,145.862 billion yuan [1] Stocks Performance - A total of 44 A-shares have surpassed the six-month moving average today, with notable stocks showing significant deviation rates [1] - The stocks with the highest deviation rates include: - Hexin Instrument (17.10%) - Dekeli (16.12%) - Lais Information (7.54%) [1] - Stocks with smaller deviation rates that have just crossed the six-month moving average include: - Junda Co., Ltd. - Taihe Intelligent - Aikodi [1] Notable Stocks - Hexin Instrument (688622) saw a price increase of 20.00% with a turnover rate of 3.28% [1] - Dekeli (688205) increased by 17.49% with a turnover rate of 23.70% [1] - Lais Information (688631) rose by 7.96% with a turnover rate of 7.58% [1] - Other notable stocks include: - Xinganjiang (873167) up by 13.11% - Anpeilong (301413) up by 10.81% [1] Additional Stocks with Positive Movement - Other stocks with positive movement include: - Haiziwang (301078) up by 4.48% - Naxinwei (688052) up by 7.92% - Tianzhun Technology (688003) up by 4.52% [1]

Core Viewpoint - HeXin Instrument has announced the transfer of its 5.3491% equity stake in Anyeep for a total price of 17.6519 million yuan, indicating a strategic move to optimize its asset structure and focus on its core business [2][4]. Summary by Sections Equity Transfer Details - HeXin Instrument will transfer its 5.3491% stake in Anyeep, corresponding to a registered capital of 386,700 yuan, to two entities: Changzhou Huada Songhe Venture Capital Partnership (Limited Partnership) and Suzhou Jingyou Management Consulting Partnership (Limited Partnership) [4]. - The stake will be divided as follows: Huada Songhe will acquire 3.0303% for 10 million yuan, and Jingyou will acquire 2.3188% for 7.6519 million yuan [4]. Financial Implications - The transaction is based on Anyeep's current market valuation and future development prospects, approved by the board and supervisory committee without requiring shareholder approval [4]. - HeXin Instrument expects a positive impact on its comprehensive income post-transaction, subject to audit results [4][5]. Company Background - Anyeep specializes in the research and manufacturing of chemical analysis and medical testing instruments, focusing on mass spectrometry technology [5]. - As of the end of 2024, Anyeep reported total assets of approximately 95.9899 million yuan, with annual revenue of 41.8749 million yuan and a net loss of 4.8234 million yuan [5]. Strategic Intent - The sale aims to optimize HeXin Instrument's asset structure and concentrate on its main business, with no significant impact on its operations or consolidated financial statements [5].

Industry Rating - The report maintains an "Outperform" rating for the scientific instruments industry, consistent with the previous rating [1]. Core Insights - The scientific instruments market in China surpassed 220 billion yuan in 2023, with a growth rate exceeding 12%. The market is dominated by high-end foreign brands, and there is a significant push for domestic alternatives driven by government policies [2][12]. - The domestic market for mass spectrometers reached 16.712 billion yuan in 2023, with foreign companies holding over 90% of the global market share. The import rate for mass spectrometers has decreased from 89% in 2018 to 81% in 2023, indicating a gradual shift towards domestic production [3][41]. - The electronic measurement instruments market is projected to exceed 40 billion yuan in 2024, with a notable focus on mid-to-high-end products. The market for oscilloscopes is expected to reach 650 million USD by 2025 [4]. Summary by Sections 1. Scientific Instruments Industry - The scientific instruments industry is characterized by high-end foreign brands dominating the market, while domestic brands struggle to gain market share. The government has introduced various policies to promote domestic innovation and application of scientific instruments [2][24]. 2. Scientific Analysis Instruments - The market for scientific analysis instruments is vast, with mass spectrometers and chromatographs showing low domestic production rates. The mass spectrometer market is expected to grow significantly, with a focus on high-resolution and triple quadrupole models as key areas for domestic manufacturers to target [25][50]. 3. Electronic Measurement Instruments - The electronic measurement instruments market is rapidly expanding, with a projected market size of 16.307 billion USD globally by 2024. The domestic market is expected to exceed 40 billion yuan, with a significant portion of high-end products still being imported [4][6]. 4. Policy Guidance - Recent government policies have aimed to support the development of domestic scientific instruments, including tax exemptions for imported instruments used in research and education, which will lower costs for research institutions [21][24].

Core Viewpoint - The article highlights the contrasting trends in employee changes among 44 listed instrument companies in China for 2024, indicating a split between companies expanding their workforce and those reducing it due to revenue pressures [1][5][10]. Group 1: Overall Trends - The overall trend shows a slight increase in employee numbers among listed instrument companies, with 24 companies expanding their workforce compared to 20 companies reducing it [5][6]. - Mindray Medical leads with a total of 21,667 employees, reflecting a 20.08% increase, driven by international expansion and digital transformation [5][6]. - Nanwei Technology shows a significant employee increase of 56.60%, attributed to its acquisition of shares in Fuli Instruments and expansion in high-margin product lines [5][6]. Group 2: Employee Reductions - 20 companies experienced varying degrees of layoffs, with HeXin Instruments seeing a drastic reduction from 684 to 276 employees, a nearly 60% drop [6][10]. - Other companies with significant layoffs include Wanyi Technology, JuGuang Technology, and Blue Shield Technology, indicating a strong correlation between workforce adjustments and revenue pressures [6][10]. Group 3: R&D Investment - Mindray Medical not only leads in total employees but also has a R&D team of 5,259, accounting for nearly 25% of its workforce, with an 18.85% increase in R&D personnel [7][10]. - Nanwei Technology's R&D personnel increased by 37.14%, with R&D investment rising by 25.84%, reflecting its commitment to high-precision material development [7][10]. - Other companies like Puyuan Precision Electric and Sand Technology also reported over 10% increases in R&D personnel, indicating active investment in new technologies [7][10]. Group 4: Industry Cycle Reflection - The changes in personnel structure reflect the development stages of various sub-industries, with life science instrument companies facing downward pressure due to market demand shifts and cost-cutting policies [9][10]. - In contrast, optical instruments and environmental monitoring companies are more active, leveraging new business opportunities and technological breakthroughs [9][10]. - The ongoing competition for high-quality R&D talent is expected to intensify as companies respond to technological innovation and domestic substitution trends [10].

证券代码：688622 证券简称：禾信仪器 公告编号：2025-041 广州禾信仪器股份有限公司 关于 2023 年限制性股票与股票期权激励计划首次授予限制性 股票第一个归属期归属结果暨股份上市公告 广州禾信仪器股份有限公司（以下简称"公司"）近日完成了 2023 年限制性 股票与股票期权激励计划（以下简称"股权激励计划"）首次授予限制性股票第一 个归属期的股份登记工作，现将有关情况公告如下： 一、本次限制性股票归属已履行的决策程序和信息披露情况 1、2023 年 8 月 4 日，公司召开第三届董事会第十六次会议，审议通过了 《关于公司<2023 年限制性股票与股票期权激励计划（草案）> 及其摘要的议案》 《关于公司<2023 年股权激励计划实施考核管理办法>的议案》《关于提请股东大 会授权董事会办理公司股权激励相关事宜的议案》等议案。同日，公司独立董事 就本次激励计划相关议案发表了明确同意的独立意见。 2、2023 年 8 月 4 日，公司召开第三届监事会第十四次会议，审议通过了 《关于公司<2023 年限制性股票与股票期权激励计划（草案）> 及其摘要的议案》 《关于公司<2023 年股权激励计划实施考核管 ...